Pharmacokinetics and safety of penciclovir following oral administration of famciclovir to cats

Sara M. Thomasy K.L. Maddy Equine Analytical Chemistry Laboratory, School of Veterinary Medicine, University of California, Davis, CA 95616.

Search for other papers by Sara M. Thomasy in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
David J. Maggs Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California, Davis, CA 95616.

Search for other papers by David J. Maggs in
Current site
Google Scholar
PubMed
Close
 BVSc
,
Nicole K. Moulin Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California, Davis, CA 95616.

Search for other papers by Nicole K. Moulin in
Current site
Google Scholar
PubMed
Close
 BS
, and
Scott D. Stanley K.L. Maddy Equine Analytical Chemistry Laboratory, School of Veterinary Medicine, University of California, Davis, CA 95616.

Search for other papers by Scott D. Stanley in
Current site
Google Scholar
PubMed
Close
 PhD

Abstract

Objective—To investigate penciclovir pharmacokinetics following single and multiple oral administrations of famciclovir to cats.

Animals—8 adult cats.

Procedures—A balanced crossover design was used. Phase I consisted of a single administration (62.5 mg, PO) of famciclovir. Phase II consisted of multiple doses of famciclovir (62.5 mg, PO) given every 8 or 12 hours for 3 days. Plasma penciclovir concentrations were assayed via liquid chromatography—mass spectrometry at fixed time points after famciclovir administration.

Results—Following a single dose of famciclovir, the dose-normalized (15 mg/kg) maximum concentration (Cmax) of penciclovir (350 ± 180 ng/mL) occurred at 4.6 ± 1.8 hours and mean ± SD apparent elimination half-life was 3.1 ± 0.9 hours. However, the dose-normalized area under the plasma penciclovir concentration-time curve extrapolated to infinity (AUC0→∞) during phase I decreased with increasing dose, suggesting either nonlinear pharmacokinetics or interindividual variability among cats. Accumulation occurred following multiple doses of famciclovir administered every 8 hours as indicated by a significantly increased dose-normalized AUC, compared with AUC0→∞ from phase 1. Dose-normalized penciclovir Cmaxfollowing administration of famciclovir every 12 or 8 hours (290 ± 150 ng/mL or 780 ± 250 ng/mL, respectively) was notably less than the in vitro concentration (3,500 ng/mL) required for activity against feline herpesvirus-1.

Conclusions and Clinical Relevance—Penciclovir pharmacokinetics following oral famciclovir administration in cats appeared complex within the dosage range studied. Famciclovir dosages of 15 mg/kg administered every 8 hours to cats are unlikely to result in plasma penciclovir concentrations with activity against feline herpesvirus-1.

Abstract

Objective—To investigate penciclovir pharmacokinetics following single and multiple oral administrations of famciclovir to cats.

Animals—8 adult cats.

Procedures—A balanced crossover design was used. Phase I consisted of a single administration (62.5 mg, PO) of famciclovir. Phase II consisted of multiple doses of famciclovir (62.5 mg, PO) given every 8 or 12 hours for 3 days. Plasma penciclovir concentrations were assayed via liquid chromatography—mass spectrometry at fixed time points after famciclovir administration.

Results—Following a single dose of famciclovir, the dose-normalized (15 mg/kg) maximum concentration (Cmax) of penciclovir (350 ± 180 ng/mL) occurred at 4.6 ± 1.8 hours and mean ± SD apparent elimination half-life was 3.1 ± 0.9 hours. However, the dose-normalized area under the plasma penciclovir concentration-time curve extrapolated to infinity (AUC0→∞) during phase I decreased with increasing dose, suggesting either nonlinear pharmacokinetics or interindividual variability among cats. Accumulation occurred following multiple doses of famciclovir administered every 8 hours as indicated by a significantly increased dose-normalized AUC, compared with AUC0→∞ from phase 1. Dose-normalized penciclovir Cmaxfollowing administration of famciclovir every 12 or 8 hours (290 ± 150 ng/mL or 780 ± 250 ng/mL, respectively) was notably less than the in vitro concentration (3,500 ng/mL) required for activity against feline herpesvirus-1.

Conclusions and Clinical Relevance—Penciclovir pharmacokinetics following oral famciclovir administration in cats appeared complex within the dosage range studied. Famciclovir dosages of 15 mg/kg administered every 8 hours to cats are unlikely to result in plasma penciclovir concentrations with activity against feline herpesvirus-1.

Contributor Notes

Presented in part at the annual forum of the American College of Veterinary Internal Medicine, Louisville, May–June 2006.

Supported by the Center for Companion Animal Health, School of Veterinary Medicine, University of California, Davis, Calif.

The authors thank Debbie Bee for technical assistance.

Address correspondance to Dr. Maggs.
  • 1.

    Ellis TM. Feline respiratory virus carriers in clinically healthy cats. Aust Vet J 1981;57:115118.

  • 2.

    Studdert MJ, Martin MC. Virus diseases of the respiratory tract of cats. 1. Isolation of feline rhinotracheitis virus. Aust Vet J 1970;46:99104.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Maggs DJ, Lappin MR, Reif JS, et al. Evaluation of serologic and viral detection methods for diagnosing feline herpesvirus-1 infection in cats with acute respiratory tract or chronic ocular disease. J Am Vet Med Assoc 1999;214:502507.

    • Search Google Scholar
    • Export Citation
  • 4.

    Hoover EA, Rohovsky MW, Griesemer RA. Experimental feline viral rhinotracheitis in the germfree cat. Am J Pathol 1970;58:269282.

  • 5.

    Gaskell RM, Povey RC. Experimental induction of feline viral rhinotracheitis virus re-excretion in FVR-recovered cats. Vet Rec 1977;100:128133.

  • 6.

    Nasisse MP, Guy JS, Stevens JB, et al. Clinical and laboratory findings in chronic conjunctivitis in cats: 91 cases (1983–1991). J Am Vet Med Assoc 1993;203:834837.

    • Search Google Scholar
    • Export Citation
  • 7.

    Johnson LR, Foley JE, De Cock HE, et al. Assessment of infectious organisms associated with chronic rhinosinusitis in cats. J Am Vet Med Assoc 2005;227:579585.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Nasisse MP, English RV, Tompkins MB, et al. Immunologic, histologic, and virologic features of herpesvirus-induced stromal keratitis in cats. Am J Vet Res 1995;56:5155.

    • Search Google Scholar
    • Export Citation
  • 9.

    Nasisse MP, Glover TL, Moore CP, et al. Detection of feline herpesvirus 1 DNA in corneas of cats with eosinophilic keratitis or corneal sequestration. Am J Vet Res 1998;59:856858.

    • Search Google Scholar
    • Export Citation
  • 10.

    Maggs DJ, Lappin MR, Nasisse MP. Detection of feline herpesvirus-specific antibodies and DNA in aqueous humor from cats with or without uveitis. Am J Vet Res 1999;60:932936.

    • Search Google Scholar
    • Export Citation
  • 11.

    Holland JL, Outerbridge CA, Affolter VK, et al. Detection of feline herpesvirus 1 DNA in skin biopsy specimens from cats with or without dermatitis. J Am Vet Med Assoc 2006;229:14421446.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Hargis AM, Ginn PE, Mansell JE, et al. Ulcerative facial and nasal dermatitis and stomatitis in cats associated with feline herpesvirus 1. Vet Dermatol 1999;10:267274.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13.

    Galle LE. Antiviral therapy for ocular viral disease. Vet Clin North Am Small Anim Pract 2004;34:639653.

  • 14.

    Stiles J. Treatment of cats with ocular disease attributable to herpesvirus infection: 17 cases (1983–1993). J Am Vet Med Assoc 1995;207:599603.

    • Search Google Scholar
    • Export Citation
  • 15.

    Nasisse MP, Guy JS, Davidson MG, et al. In vitro susceptibility of feline herpesvirus-1 to vidarabine, idoxuridine, trifluridine, acyclovir, or bromovinyldeoxyuridine. Am J Vet Res 1989;50:158160.

    • Search Google Scholar
    • Export Citation
  • 16.

    Maggs DJ, Clarke HE. In vitro efficacy of ganciclovir, cidofovir, penciclovir, foscarnet, idoxuridine, and acyclovir against feline herpesvirus type-1. Am J Vet Res 2004;65:399403.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17.

    Owens JG, Nasisse MP, Tadepalli SM, et al. Pharmacokinetics of acyclovir in the cat. J Vet Pharmacol Ther 1996;19:488490.

  • 18.

    Nasisse MP, Dorman DC, Jamison KC, et al. Effects of valacyclovir in cats infected with feline herpesvirus 1. Am J Vet Res 1997;58:11411144.

    • Search Google Scholar
    • Export Citation
  • 19.

    Filer CW, Ramji JV, Allen GD, et al. Metabolic and pharmacokinetic studies following oral administration of famciclovir to the rat and dog. Xenobiotica 1995;25:477490.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 20.

    Gibaldi M, Perrier D. Noncompartmental analysis based on statistical moment theory. In: Gibaldi M, Perrier D, eds. Pharmaco-kinetics. 2nd ed. New York: Marcel Dekker Inc, 1982;409418.

    • Search Google Scholar
    • Export Citation
  • 21.

    Pue MA, Pratt SK, Fairless AJ, et al. Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750 mg to healthy volunteers. J Antimicrob Chemother 1994;33:119127.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 22.

    Clarke SE, Harrell AW, Chenery RJ. Role of aldehyde oxidase in the in vitro conversion of famciclovir to penciclovir in human liver. Drug Metab Dispos 1995;23:251254.

    • Search Google Scholar
    • Export Citation
  • 23.

    Dick RA, Kanne DB, Casida JE. Identification of aldehyde oxidase as the neonicotinoid nitroreductase. Chem Res Toxicol 2005;18:317323.

  • 24.

    Gill KS, Wood MJ. The clinical pharmacokinetics of famciclovir. Clin Pharmacokinet 1996;31:18.

  • 25.

    Physicians' desk reference. 60th ed. Montvale, NJ: Thomson, 2007;22112214.

Advertisement